April1, 2019 - The case was voluntarily dismissed.

July 19, 2018 - The court granted in part and denied in part the defendants' motion to dismiss.

October 2, 2017 - A motion to dismiss the amended complaint was filed.

April 6, 2017 - The case was transferred to the U.S. District Court for the District of Massachusetts.

February 27, 2017 - An amended complaint was filed.

August 2, 2016 - An investor in shares of Keryx Biopharmaceuticals (NASDAQ: KERX) filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Keryx Biopharmaceuticals in connection with certain allegedly false and misleading statements made between February 25, 2016, and August 1, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Keryx Biopharmaceuticals (NASDAQ: KERX) common shares between February 25, 2016, and August 1, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 25, 2016, and August 1, 2016 the defendants made allegedly false and/or misleading statements and/or failed to disclose that Keryx Biopharmaceuticals was experiencing production-related difficulties in converting API to finished drug product, that the issue was resulting in decreased production yields of finished drug product, that, as a result, the Company would, and did exhaust its reserve of finished drug product, and that, as a result of the foregoing, Defendants’ statements about Keryx Biopharmaceuticals’ business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Keryx Biopharmaceuticals reported that its annual total Revenue rose from $7.00 million in 2013 to $13.68 million in 2015 and that its Net Loss increased from $46.73 million in 2013 to $123.14 million in 2015.

Shares of Keryx Biopharmaceuticals (NASDAQ: KERX) declined from $18.19 per share in August 2014 to as low as $3.29 per share in January 2016.

On August, 1, 2016 Keryx Biopharmaceuticals announced an interruption in the supply of Auryxia® (ferric citrate) tablets due to a production-related issue converting active pharmaceutical ingredient to finished drug product. Keryx Biopharmaceuticals said it expects to make Auryxia available to patients when supply is back to adequate levels. Additionally, Keryx Biopharmaceuticals has withdrawn its 2016 financial guidance.

Shares of Keryx Biopharmaceuticals (NASDAQ: KERX) declined to as low as $4.02 per share on August 2, 2016.